CheckMyRecalls

Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release…

Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USP

Published
30 Apr 2025
Units affected
2 products
Agency
FDA
Country
United States

The hazard

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10

Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922

Brand / company
Breckenridge Pharmaceutical, Inc
Codes / lots
Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027 | Lot # 230201C, exp. date 01/2026 230471C, exp. date 01/2026 230288C, exp. date 01/2026
Distribution
US Nationwide.
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 30 Apr 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.